Bacillus subtilis SF106 and Bacillus clausii SF174 spores reduce the inflammation and modulate the gut microbiota in a colitis model

What is it about?

Inflammatory intestinal disease (IBD) is a group of inflammatory conditions of the gastro-intestinal tract that includes the Crohn's disease, mostly affecting both small and large intestine and the ulcerative colitis (UC), primarily affecting colon and rectum. The incidence of IBD is rising globally and it has been suggested that particular environmental exposures occurring early in life may trigger IBD in genetically susceptible individuals. In addition, emerging evidence supports a relationship between disease progression and changes in the gut microbiota. Therefore, the study of the gut microbiota will provide insights into disease pathogenesis and lead to microbiome-based interventions for IBD. _x000D_ _x000D_ The oral use of probiotics is widely accepted and is based on the capacity of some bacteria to reduce inflammation, protect gut barrier integrity and reshape the microbiota by favouring the presence of beneficial microbes. We analyzed the effects of the oral administration of probiotic spores in a murine model of experimental colitis. A reduction of colitis symptoms and a reshape of the microbiota with an increased abundance of beneficial bacteria has been obeserved, indicating the positive effects of the tested probiotics._x000D_

Featured Image